Bristol-Myers Squibb said it would close its Wallingford, CT facility early in 2018. About 200 employees from Wallingford and Waltham, MA will be relocated to a facility in Cambridge, MA. About 500 employees will be relocated from Wallingford to a facility elsewhere in Connecticut.

In Cambridge, Bristol-Myers Squibb scientists will focus on the company’s ongoing discovery efforts in genetically defined diseases, molecular discovery technologies, and discovery platform chemistry.